Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Rhea-AI Summary

Pharvaris (Nasdaq: PHVS) announced the acceptance of two abstracts for presentation at the CIIC Spring 2024 Conference regarding their oral bradykinin B2 receptor antagonists for hereditary angioedema attacks. The presentations will focus on early-onset response and efficacy/safety of Deucrictibant in patients.

ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.

Presentation details:

• Title: Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
  Format: Digital Abstract Display Board
  Date, time: Saturday, April 13, 11:00-11:20 a.m. CDT (12:00-12:20 p.m. EDT)
• Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
  Presenter: John Anderson, M.D.
  Format: E-Poster Presentation
  Date, time: Saturday, April 13, 11:20 a.m.-12:00 p.m. CDT (12:20-1:00 p.m. EDT)

The posters and associated presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentation sessions at: https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Building on its deep-seated roots in HAE, Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.

FAQ

What is the focus of the abstracts accepted by Pharvaris for presentation at the CIIC Spring 2024 Conference?

The abstracts focus on the oral bradykinin B2 receptor antagonists developed by Pharvaris to treat and prevent hereditary angioedema attacks.

When and where will the CIIC Spring 2024 Conference take place?

The CIIC Spring 2024 Conference will be held from April 12-13, 2024, in Arlington, TX.

Who is the presenter of the Efficacy and Safety abstract at the conference?

John Anderson, M.D., will present the Efficacy and Safety abstract on Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks.

Where can investors access the posters and presentation slides related to the abstracts?

Investors can access the posters and presentation slides on the Pharvaris website's Investors section at the beginning of the respective presentation sessions.